Screener
ArriVent BioPharma, Inc. AVBP Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 54,724 | 6,516 |
| Proceeds from the exercise of stock options | 149 | 293 |
| Payment of deferred financing costs | — | (50) |
| Net cash provided by financing activities | 54,873 | 6,759 |
| Net increase (decrease) in cash and cash equivalents | 16,563 | (24,428) |
| Cash and cash equivalents at beginning of the year | 45,540 | 74,293 |
| Cash and cash equivalents at end of the year | $62,103 | $49,865 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s net change in cash?
- ArriVent BioPharma, Inc. (AVBP) reported net change in cash of $16.56M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s net change in cash changed year-over-year?
- ArriVent BioPharma, Inc.'s net change in cash increased by 167.8% year-over-year, from -$24.43M to $16.56M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about ArriVent BioPharma, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude